This report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
The whole genome and exome sequencing market size has grown exponentially in recent years. It will grow from $2.02 billion in 2024 to $2.53 billion in 2025 at a compound annual growth rate (CAGR) of 24.8%. The growth in the historic period can be attributed to decreasing sequencing costs, rise in genetic disorders, clinical applications, genomic data repositories, advancements in bioinformatics.
The whole genome and exome sequencing market size is expected to see exponential growth in the next few years. It will grow to $6.14 billion in 2029 at a compound annual growth rate (CAGR) of 24.9%. The growth in the forecast period can be attributed to population genomics initiatives, rising demand for precision medicine, advancements in single-cell sequencing, expansion of non-invasive prenatal testing (NIPT), application in rare disease research. Major trends in the forecast period include expanded clinical adoption, rapid advancements in sequencing technologies, rise of population-scale genomic studies, integration of artificial intelligence (AI) and machine learning (ML), expanding applications in oncology.
The increasing interest in personalized medicine is anticipated to drive the expansion of the whole genome and exome sequencing market in the coming years. Personalized medicine adopts a tailored approach to healthcare, considering individual patient characteristics such as genetics, environment, and lifestyle in treatment decisions. Whole genome and exome sequencing play a pivotal role in personalized medicine by offering a comprehensive analysis of an individual's genetic composition, enabling healthcare interventions customized to their specific genetic, environmental, and lifestyle factors. For example, as of October 2022, the Personalized Medicine Coalition (PMC) projects over 75,000 genetic testing products and 300 personalized medicines to be available on the market. Additionally, the Food and Drug Administration's Center for Drug Evaluation and Research (CDER) approved 37 new molecular entities (NMEs) in 2022, with approximately 34% classified as personalized among the 35 therapeutic NMEs. Consequently, the growing demand for personalized medicine is fueling the expansion of the whole genome and exome sequencing market.
Major players in the whole genome and exome sequencing markets are intensifying their efforts towards developing cutting-edge technological solutions, notably ultra-fast NGS (next-generation sequencing) analysis, to gain a competitive advantage. This innovation facilitates the rapid processing of NGS data, drastically reducing analysis time. For example, in January 2023, QIAGEN Digital Insights (QDI), a US-based bioinformatics company, introduced an ultra-fast NGS analysis platform. This platform boasts features such as processing a whole genome in just 25 minutes at a cost of $1 in cloud computing expenses, promoting efficiency, affordability, and scalability. Its technological breakthrough significantly enhances the speed and accessibility of genomic data analysis, playing a crucial role in the whole genome and exome sequencing market by enabling swift decision-making and wider adoption of personalized medicine.
In January 2023, QIAGEN, a multinational corporation headquartered in Germany and specializing in sample technologies and molecular insights products, acquired Verogen for an undisclosed sum. This acquisition bolsters QIAGEN's presence in the human identification and forensics market, consolidating its leadership position and facilitating the creation of more comprehensive solutions with potential implications for the entire genome and exome sequencing market. Verogen, based in the United States, is a biotech company that offers next-generation sequencing (NGS) tools and services, including whole genome and exome sequencing.
Major companies operating in the whole genome and exome sequencing market report are Siemens AG, Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Cytiva (Danaher Corporation), Laboratory Corporation of America Holdings (Labcorp), Eurofins Scientific SE, Agilent Technologies Inc., Illumina Inc., Canon Medical Systems Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V, Neusoft Corporation, BGI Genomics, Mirion Technologies (Capintec) Inc., Novogene Co., Oxford Nanopore Technologies Inc., LANDAUER, Pacific Biosciences of California Inc., Digirad Corporation, Berthold Technologies GmbH & Co.KG, GENEWIZ Inc., Incom Inc., Lucerno Dynamics LLC, Absolute Imaging Inc., Mediso Ltd., Ashby Gorman Baker Ltd., DDD-Diagnostic AS, SurgicEye GmbH, CMR Naviscan.
North America was the largest region in the whole genome and exome sequencing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the whole genome and exome sequencing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the whole genome and exome sequencing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The whole genome and exome sequencing market consists of revenues earned by entities by providing services such as genetic profiling, variant identification, personalized medicine solutions, and comprehensive genomic analysis. The market value includes the value of related goods sold by the service provider or included within the service offering. The whole genome and exome sequencing market also includes sales of exome capture kits, benchtop sequencer, and sample preparation instrutments. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
Whole genome sequencing (WGS) and exome sequencing (ES) are advanced genetic analysis methodologies aimed at deciphering an organism's complete DNA sequence and specifically targeting the protein-coding regions of the genome. These techniques play a crucial role in diagnosing genetic disorders and identifying cancer-related mutations.
The primary product categories in WGS and ES comprise kits and instruments, where kits encompass a collection of related products packaged together for simplified inventory management. Various workflows such as whole genome sequencing (WGS) and whole exome sequencing (WES) are utilized across multiple applications including diagnostics, cancer research, monogenic disorders, drug development, personalized medicine, agriculture, and animal research. End users encompass diverse entities such as research centers, academic institutions, governmental bodies, hospitals, pharmaceutical and biotechnology companies, among others.
The whole genome and exome sequencing market research report is one of a series of new reports that provides whole genome and exome sequencing market statistics, including whole genome and exome sequencing industry global market size, regional shares, competitors with a whole genome and exome sequencing market share, detailed whole genome and exome sequencing market segments, market trends and opportunities, and any further data you may need to thrive in the whole genome and exome sequencing industry. This whole genome and exome sequencing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The whole genome and exome sequencing market size has grown exponentially in recent years. It will grow from $2.02 billion in 2024 to $2.53 billion in 2025 at a compound annual growth rate (CAGR) of 24.8%. The growth in the historic period can be attributed to decreasing sequencing costs, rise in genetic disorders, clinical applications, genomic data repositories, advancements in bioinformatics.
The whole genome and exome sequencing market size is expected to see exponential growth in the next few years. It will grow to $6.14 billion in 2029 at a compound annual growth rate (CAGR) of 24.9%. The growth in the forecast period can be attributed to population genomics initiatives, rising demand for precision medicine, advancements in single-cell sequencing, expansion of non-invasive prenatal testing (NIPT), application in rare disease research. Major trends in the forecast period include expanded clinical adoption, rapid advancements in sequencing technologies, rise of population-scale genomic studies, integration of artificial intelligence (AI) and machine learning (ML), expanding applications in oncology.
The increasing interest in personalized medicine is anticipated to drive the expansion of the whole genome and exome sequencing market in the coming years. Personalized medicine adopts a tailored approach to healthcare, considering individual patient characteristics such as genetics, environment, and lifestyle in treatment decisions. Whole genome and exome sequencing play a pivotal role in personalized medicine by offering a comprehensive analysis of an individual's genetic composition, enabling healthcare interventions customized to their specific genetic, environmental, and lifestyle factors. For example, as of October 2022, the Personalized Medicine Coalition (PMC) projects over 75,000 genetic testing products and 300 personalized medicines to be available on the market. Additionally, the Food and Drug Administration's Center for Drug Evaluation and Research (CDER) approved 37 new molecular entities (NMEs) in 2022, with approximately 34% classified as personalized among the 35 therapeutic NMEs. Consequently, the growing demand for personalized medicine is fueling the expansion of the whole genome and exome sequencing market.
Major players in the whole genome and exome sequencing markets are intensifying their efforts towards developing cutting-edge technological solutions, notably ultra-fast NGS (next-generation sequencing) analysis, to gain a competitive advantage. This innovation facilitates the rapid processing of NGS data, drastically reducing analysis time. For example, in January 2023, QIAGEN Digital Insights (QDI), a US-based bioinformatics company, introduced an ultra-fast NGS analysis platform. This platform boasts features such as processing a whole genome in just 25 minutes at a cost of $1 in cloud computing expenses, promoting efficiency, affordability, and scalability. Its technological breakthrough significantly enhances the speed and accessibility of genomic data analysis, playing a crucial role in the whole genome and exome sequencing market by enabling swift decision-making and wider adoption of personalized medicine.
In January 2023, QIAGEN, a multinational corporation headquartered in Germany and specializing in sample technologies and molecular insights products, acquired Verogen for an undisclosed sum. This acquisition bolsters QIAGEN's presence in the human identification and forensics market, consolidating its leadership position and facilitating the creation of more comprehensive solutions with potential implications for the entire genome and exome sequencing market. Verogen, based in the United States, is a biotech company that offers next-generation sequencing (NGS) tools and services, including whole genome and exome sequencing.
Major companies operating in the whole genome and exome sequencing market report are Siemens AG, Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Cytiva (Danaher Corporation), Laboratory Corporation of America Holdings (Labcorp), Eurofins Scientific SE, Agilent Technologies Inc., Illumina Inc., Canon Medical Systems Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V, Neusoft Corporation, BGI Genomics, Mirion Technologies (Capintec) Inc., Novogene Co., Oxford Nanopore Technologies Inc., LANDAUER, Pacific Biosciences of California Inc., Digirad Corporation, Berthold Technologies GmbH & Co.KG, GENEWIZ Inc., Incom Inc., Lucerno Dynamics LLC, Absolute Imaging Inc., Mediso Ltd., Ashby Gorman Baker Ltd., DDD-Diagnostic AS, SurgicEye GmbH, CMR Naviscan.
North America was the largest region in the whole genome and exome sequencing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the whole genome and exome sequencing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the whole genome and exome sequencing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The whole genome and exome sequencing market consists of revenues earned by entities by providing services such as genetic profiling, variant identification, personalized medicine solutions, and comprehensive genomic analysis. The market value includes the value of related goods sold by the service provider or included within the service offering. The whole genome and exome sequencing market also includes sales of exome capture kits, benchtop sequencer, and sample preparation instrutments. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
Whole genome sequencing (WGS) and exome sequencing (ES) are advanced genetic analysis methodologies aimed at deciphering an organism's complete DNA sequence and specifically targeting the protein-coding regions of the genome. These techniques play a crucial role in diagnosing genetic disorders and identifying cancer-related mutations.
The primary product categories in WGS and ES comprise kits and instruments, where kits encompass a collection of related products packaged together for simplified inventory management. Various workflows such as whole genome sequencing (WGS) and whole exome sequencing (WES) are utilized across multiple applications including diagnostics, cancer research, monogenic disorders, drug development, personalized medicine, agriculture, and animal research. End users encompass diverse entities such as research centers, academic institutions, governmental bodies, hospitals, pharmaceutical and biotechnology companies, among others.
The whole genome and exome sequencing market research report is one of a series of new reports that provides whole genome and exome sequencing market statistics, including whole genome and exome sequencing industry global market size, regional shares, competitors with a whole genome and exome sequencing market share, detailed whole genome and exome sequencing market segments, market trends and opportunities, and any further data you may need to thrive in the whole genome and exome sequencing industry. This whole genome and exome sequencing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Whole Genome and Exome Sequencing Market Characteristics3. Whole Genome and Exome Sequencing Market Trends and Strategies4. Whole Genome and Exome Sequencing Market - Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, Covid and Recovery on the Market32. Global Whole Genome and Exome Sequencing Market Competitive Benchmarking and Dashboard33. Key Mergers and Acquisitions in the Whole Genome and Exome Sequencing Market34. Recent Developments in the Whole Genome and Exome Sequencing Market
5. Global Whole Genome and Exome Sequencing Growth Analysis and Strategic Analysis Framework
6. Whole Genome and Exome Sequencing Market Segmentation
7. Whole Genome and Exome Sequencing Market Regional and Country Analysis
8. Asia-Pacific Whole Genome and Exome Sequencing Market
9. China Whole Genome and Exome Sequencing Market
10. India Whole Genome and Exome Sequencing Market
11. Japan Whole Genome and Exome Sequencing Market
12. Australia Whole Genome and Exome Sequencing Market
13. Indonesia Whole Genome and Exome Sequencing Market
14. South Korea Whole Genome and Exome Sequencing Market
15. Western Europe Whole Genome and Exome Sequencing Market
16. UK Whole Genome and Exome Sequencing Market
17. Germany Whole Genome and Exome Sequencing Market
18. France Whole Genome and Exome Sequencing Market
19. Italy Whole Genome and Exome Sequencing Market
20. Spain Whole Genome and Exome Sequencing Market
21. Eastern Europe Whole Genome and Exome Sequencing Market
22. Russia Whole Genome and Exome Sequencing Market
23. North America Whole Genome and Exome Sequencing Market
24. USA Whole Genome and Exome Sequencing Market
25. Canada Whole Genome and Exome Sequencing Market
26. South America Whole Genome and Exome Sequencing Market
27. Brazil Whole Genome and Exome Sequencing Market
28. Middle East Whole Genome and Exome Sequencing Market
29. Africa Whole Genome and Exome Sequencing Market
30. Whole Genome and Exome Sequencing Market Competitive Landscape and Company Profiles
31. Whole Genome and Exome Sequencing Market Other Major and Innovative Companies
35. Whole Genome and Exome Sequencing Market High Potential Countries, Segments and Strategies
36. Appendix
Executive Summary
Whole Genome And Exome Sequencing Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on whole genome and exome sequencing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for whole genome and exome sequencing? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The whole genome and exome sequencing market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Product Type: Kits; Instruments2) By Workflow: Whole Genome Sequencing (WGS); Whole Exome Sequencing (WES)
3) By Applications: Diagnostics; Cancer; Monogenic Disorders; Diabetes; Drug Discovery And Development; Personalized Medicine; Agriculture And Animal Research; Other Applications
4) By End user: Research Center; Academic And Government Institutions; Hospitals And Clinics; Pharmaceutical And Biotechnology Companies; Other End Users
Subsegments:
1) By Kits: Library Preparation Kits; Target Enrichment Kits; DNA Extraction Kits2) By Instruments: Next-Generation Sequencing (NGS) Systems; Sanger Sequencing Systems; Third-Generation Sequencing Systems
Key Companies Mentioned: Siemens AG; Hoffmann-La Roche Ltd.; Thermo Fisher Scientific Inc.; Cytiva (Danaher Corporation); Laboratory Corporation of America Holdings (Labcorp)
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
Some of the major companies featured in this Whole Genome and Exome Sequencing market report include:- Siemens AG
- Hoffmann-La Roche Ltd.
- Thermo Fisher Scientific Inc.
- Cytiva (Danaher Corporation)
- Laboratory Corporation of America Holdings (Labcorp)
- Eurofins Scientific SE
- Agilent Technologies Inc.
- Illumina Inc.
- Canon Medical Systems Corporation
- Bio-Rad Laboratories Inc.
- QIAGEN N.V
- Neusoft Corporation
- BGI Genomics
- Mirion Technologies (Capintec) Inc.
- Novogene Co.
- Oxford Nanopore Technologies Inc.
- LANDAUER
- Pacific Biosciences of California Inc.
- Digirad Corporation
- Berthold Technologies GmbH & Co.KG
- GENEWIZ Inc.
- Incom Inc.
- Lucerno Dynamics LLC
- Absolute Imaging Inc.
- Mediso Ltd.
- Ashby Gorman Baker Ltd.
- DDD-Diagnostic AS
- SurgicEye GmbH
- CMR Naviscan
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | March 2025 |
| Forecast Period | 2025 - 2029 |
| Estimated Market Value ( USD | $ 2.53 Billion |
| Forecasted Market Value ( USD | $ 6.14 Billion |
| Compound Annual Growth Rate | 24.9% |
| Regions Covered | Global |
| No. of Companies Mentioned | 29 |
